Case Report: Iparomlimab and Tuvonralimab-based therapy for epithelioid malignant peritoneal mesothelioma: a three-case series
The QL1706-based therapy achieved disease control in all three patients with EMPM who had limited conventional treatment options, including a durable response in an elderly patient with PD‑L1-negative disease and rapid tumor regression with QL1706 monotherapy.
This case report describes three patients with epithelioid malignant peritoneal mesothelioma (EMPM) who were treated with QL1706 (Iparomlimab+Tuvonralimab) either as monotherapy or in combination with bevacizumab or lenvatinib. Clinical responses were assessed by RECIST 1.1; one patient achieved stable disease (~7 months) with QL1706 + bevacizumab, two achieved partial responses (~>10 months and ~4 months) with QL1706 + lenvatinib or QL1706 monotherapy. The report highlights safety and efficacy signals of fixed‑ratio dual checkpoint inhibition in this rare malignancy.
EMPM is a rare, aggressive malignancy with limited systemic treatment options. This series suggests that fixed‑ratio PD‑1/CTLA‑4 blockade, alone or combined with anti‑angiogenic agents, can produce meaningful clinical benefit and may expand therapeutic avenues for patients who cannot undergo cytoreductive surgery or intensive chemotherapy.
Bizonyítékszint: Korai humán adat. Kis vagy feltáró emberi adat.
Kapcsolódó jelek
- Beyond the Five-Year Milestone: Long‑term Survivorship of Melanoma Patients Treated Off‑Trial with anti‑PD‑1
- Uveal Melanoma – Trials in Disease – Overview of Information and Clinical Research
- A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
- Melanoma Research
- The Clinical Trial Landscape for Melanoma Therapies